Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 5/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448511 | 0.95 | EED (0.39) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL450607 | 0.90 | EED (0.41) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL446625 | 0.80 | EED (0.43) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL347860 | 0.78 | MTNR1A (0.47) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL6952349 | 0.78 | EED (0.42) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL2096585 | 0.78 | EED (0.42) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL8835248 | 0.78 | EED (0.42) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL2095886 | 0.77 | KCNA3 (0.43) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL2096511 | 0.75 | EED (0.40) | EEDKCNA3MTNR1AMTNR1BOPRM1 | |
| SCHEMBL3793134 | 0.74 | MTNR1A (0.49) | EEDKCNA3MTNR1AMTNR1BOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | EED 3331/4885KCNA3 1786/4885MTNR1A 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.